As of May 27, 2025, Trillium Therapeutics Inc (TRIL.TO) reports a EV/EBITDA of -48.14.
EV/EBITDA evaluates a company's total value relative to its earnings before interest, taxes, depreciation, and amortization, useful for comparing firms with different capital structures.
Comparing Trillium Therapeutics Inc's EV/EBITDA to Peers
To better understand Trillium Therapeutics Inc's position, it's useful to compare its EV/EBITDA against industry peers. Below are selected comparisons:
| Company | EV/EBITDA |
|---|---|
| Trillium Therapeutics Inc (TRIL.TO) | -48.14 |
| Mersana Therapeutics Inc (MRSN) | 0.56 |
| Shattuck Labs Inc (STTK) | 0.14 |
| 4D Molecular Therapeutics Inc (FDMT) | -0.07 |
| Keros Therapeutics Inc (KROS) | -0.15 |
| Atara Biotherapeutics Inc (ATRA) | -0.76 |
Compared to its competitors, Trillium Therapeutics Inc's EV/EBITDA is lower than all peers, which may indicate undervaluation or market concerns about future performance.